Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Parasite is a general term for an organism that lives on or inside another organism (the host), obtaining nutrients at the host’s expense and often causing harm. The term "parasite" does not refer to a single molecule, protein, receptor, or gene; rather, it encompasses a vast range of organisms from different biological kingdoms and phyla. Medically important parasites are broadly classified into three main groups:\n\n- Protozoa: Single-celled eukaryotes such as Plasmodium spp. (malaria), Giardia lamblia, and Entamoeba histolytica.\n- Helminths: Multicellular worms including roundworms (Ascaris lumbricoides), flatworms (Schistosoma spp., tapeworms like Taenia spp.), and thorny-headed worms[1][2][5][7].\n- Arthropods: Insects and arachnids such as mosquitoes, ticks, fleas, lice—some act as ectoparasites or vectors for other pathogens[1][2][5].\n\nParasitic infections are responsible for significant global morbidity and mortality—malaria alone causes over 400,000 deaths annually[5]. Neglected tropical diseases caused by parasites affect over a billion people worldwide.\n\nBecause "parasite" refers to an entire class of organisms rather than a specific molecular target or receptor:\n\nThere is something incorrect with using "Parasites" as the name of a drug target in the context of molecular pharmacology or drug discovery. It is too broad; drugs typically target specific molecules within these organisms (e.g., enzymes like dihydrofolate reductase in malaria parasites) rather than the whole parasite itself.\n\nFor structured data extraction purposes:\n\nNote on interacting_drugs & mechanism_of_action: Many drugs treat parasitic infections by targeting specific proteins/enzymes unique to each parasite species—for example antimalarials like artemisinin target heme metabolism in Plasmodium, while antihelminthics like albendazole inhibit microtubule formation in nematodes—but there is no single drug that targets all “parasites” generically[7]. Thus these fields should be left blank unless referring to individual parasite species/proteins.\n\nIn summary: “Parasite” is not an appropriate canonical name for a therapeutic molecular target; it refers instead to diverse pathogenic organisms spanning multiple taxonomic groups[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Parasite.